NurExone Biologic Continues Expansion of U.S. Presence and Awareness with Prestigious Conference Presentation TORONTO and HAIFA, Israel, Feb. 14, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (Germany: J90) (“NurExone” or the “Company”) is excited to announce that it will be...

NurExone Forms Exo-Top Inc. in the U.S. for Exosome Manufacture and Commercialization NurExone Biologic Inc. announces formation of a U.S.-based subsidiary, Exo-Top Inc. for fully characterized GMP Exosome production.

NurExone Biologic Secures Master Cell Bank NurExone Biologic Secures Master Cell Bank - a Key Milestone for Therapeutic Exosome Production

NurExone Biologic Achieves Key Milestone in Support of Robust Exosome Manufacturing Process NurExone’s reliable production from diverse biological sources allows NurExone to optimize exosome production with consistency and efficiency

NurExone’s Intellectual Property Portfolio Expands NurExone's Intellectual Property portfolio is expanding to encompass processes and compositions related to exosomes in large-scale production